Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Capital Markets Event

26th Jan 2016 07:00

RNS Number : 9287M
Futura Medical PLC
26 January 2016
 

For immediate release

26 January 2016

 

 

Futura Medical plc

("Futura" or the "Company")

 

Capital Markets Event

 

 

Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, will this afternoon host a capital markets event for equity analysts and institutional investors.

 

The event will be webcast. To access the webcast live, please log on to the following web address approximately 5 minutes before 3.15pm GMT today:

http://vm.buchanan.uk.com/2016/futuramedical260116/registration.htm

 

A recording of the webcast will be made available for several days from 27 January 2016 at www.futuramedical.com and at www.buchanan.uk.com.

 

The capital markets event will provide details of progress across the Company's portfolio of products. On CSD500, Futura's erectogenic condom, attendees of the event will be informed that the Company continues to receive positive stability data from its modified manufacturing process. This data indicates an extended shelf life for the product in line with distributors' requirements.

 

The presentations on MED2002, Futura's novel gel for erectile dysfunction, will include an update on recruitment to the current pivotal clinical study, which now has a total of 171 patients enrolled in the run-in phase of the study. The announcement of headline data from the study remains on track for the end of H1 2016.

 

Presentations on the Company's topical pain relief products, TPR100 (diclofenac) and TIB200 (ibuprofen), will include an overview of the potential regulatory pathway for the products, which remains in line with previous announcements, as well as an outline of the likely commercialisation strategy.

 

Analysts and investors who would like to attend the capital markets event, please contact Buchanan at the details below.

 

For further information please contact:

Futura Medical plc

James Barder, Chief Executive

Tel: +44 (0) 1483 685 670

Email to: [email protected]

www.futuramedical.com

 

N+1 Singer (Nominated Adviser and Broker)

Aubrey Powell / Liz Yong / Tom SmaleCorporate Finance

 

Tel:+44 (0) 20 7496 3000

For media enquiries please contact:

Buchanan

Mark Court / Sophie Cowles / Stephanie Watson

Tel: +44 (0) 20 7466 5000

 

 

Notes to Editors

 

Futura Medical plc

 

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

 

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.

 

www.futuramedical.com

 

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCEAKFSALSKEFF

Related Shares:

Futura Medical
FTSE 100 Latest
Value8,275.66
Change0.00